Download Files:
Products Details
Product Description
– Zorubicin (Rubidazon) is a derivative of Daunorubicin (HY-13062A). Zorubicin interacts with topoisomerase II and inhibits DNA polymerases. Zorubicin can be used for the research of acute leukemias and sarcomas[1][2][3][4][5].
Web ID
– HY-106556
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C34H35N3O10
References
– [1]Alberts DS, Van Daalen Wetters T. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system. Br J Cancer. 1976 Jul;34(1):64-8.|[2]Barlogie B, et al. Kinetic response to cultured human lymphoid cells to rubidazone. J Natl Cancer Inst. 1978 Feb;60(2):279-82.|[3]Herman EH, Young RS. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog. Cancer Treat Rep.|[4]Sartiano GP, et al. Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential inhibition of DNA polymerase alpha. J Antibiot (Tokyo). 1979 Oct;32(10):1038-45. |[5]Akerman KJ, et al. Gold(III) macrocycles: nucleotide-specific unconventional catalytic inhibitors of human topoisomerase I. J Am Chem Soc. 2014 Apr 16;136(15):5670-82.
CAS Number
– 54083-22-6
Molecular Weight
– 645.66
SMILES
– OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](/C(C)=N/NC(C5=CC=CC=C5)=O)(O)C[C@@H]4O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O)N
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– DNA/RNA Synthesis;Topoisomerase
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
